CDSCO approves Zydus, SIFI pact to launch Intraocular Lenses in India

Published On 2019-04-30 04:45 GMT   |   Update On 2021-08-16 08:25 GMT

"SIFI's innovative IOLs (Intraocular lenses) have been approved by the Indian Central Drugs Standards Control Organisation(CDSCO) (Directorate General of Health Services) and Ministry of Health & Family Welfare (Medical Device and Diagnostic Division)," Zydus Cadila said in a regulatory filing.


New Delhi: Drug firm Zydus Cadila Tuesday said that the company has tied up with Italian ophthalmic company, SIFI to market innovative IOLs (Intraocular lenses) and surgical products developed in Italy and licensed in India by SIFI.


"SIFI's innovative IOLs (Intraocular lenses) have been approved by the Indian Central Drugs Standards Control Organisation(CDSCO) (Directorate General of Health Services) and Ministry of Health & Family Welfare (Medical Device and Diagnostic Division)," Zydus Cadila said in a regulatory filing.


Zydus and SIFI look forward to bring such innovations to India and to the entire South Asia region in order to empower surgeons with advanced technology and consequently better the quality of vision and life of patients, the company added.


These surgical devices represent the most advanced solution for cataract refractive surgery and the correction of astigmatism (a condition where the cornea is irregularly shaped) and presbyopia (natural loss of near focusing ability that occurs with age).


'Refractive cataract' is nowadays at the frontier of cataract surgery as it combines clouded lens removal
to the simultaneous correction of refractive errors such as myopia, hypermetropia, astigmatism and
presbyopia, in order to free the patient from wearing glasses following the surgery.


Also Read: Zydus Cadila gets final USFDA nod for Leflunomide tablets to treat arthritis


The highly advanced IOLs for this purpose are the EDOF (Extended Depth of Focus) lenses that present an optical plate with a continuous series of focuses, able to ensure a continuum correction from far to near in case of presbyopia and in case of astigmatism to provide compensation of the corneal abnormal curvature.







Cadila Healthcare Ltd is headquartered at Ahmedabad in Gujarat state of western India. The company is one of the leading pharmaceutical companies in India. It is a manufactures, discovers, develops, and markets a broad range of healthcare therapies. While SIFI is an Italian ophthalmic company, focused on eye care since 1935.


SIFI designs, manufactures and markets innovative pharmaceutical speciality products, nutraceuticals, surgical and medical devices. Headquartered in Catania, Sicily, SIFI operates directly in Italy, France, Spain, Romania, Turkey and Mexico with a staff of more than 400 people worldwide.


Since June 2015, SIFI is backed by the private equity 21 Invest to support the company's international expansion and portfolio development strategy.






Tags:    
Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News